Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).
Authors
Evan Justin Walker
University of California, San Francisco, San Francisco, CA
Evan Justin Walker , Christos Fountzilas , Erkut Hasan Borazanci , Anthony F. Shields , James Thomas D'Olimpio , J. Randolph Hecht , Shou-Ching Tang , Glenn Michelson , Lorna Liganor , Sangsook Ahn Cho , Andrew H. Ko
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05249101
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 666)
DOI
10.1200/JCO.2024.42.3_suppl.666
Abstract #
666
Poster Bd #
L15
Abstract Disclosures
Similar Posters
First Author: Evan Justin Walker
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni
Poster
2016 Gastrointestinal Cancers Symposium
A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic adenocarcinoma.
First Author: Andrea S. Teague
Poster
2022 ASCO Gastrointestinal Cancers Symposium
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.
First Author: Tanios S. Bekaii-Saab